Pharming Group (NASDAQ:PHAR) Given "Buy" Rating at HC Wainwright

Pharming Group (NASDAQ:PHAR - Get Free Report)'s stock had its "buy" rating restated by research analysts at HC Wainwright in a report issued on Tuesday,Benzinga reports. They presently have a $37.00 price objective on the stock. HC Wainwright's price target would suggest a potential upside of 320.45% from the stock's previous close.

Several other equities research analysts have also recently commented on PHAR. Oppenheimer lowered their target price on Pharming Group from $31.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, October 28th. Jefferies Financial Group began coverage on Pharming Group in a report on Monday, December 9th. They set a "buy" rating and a $14.00 target price on the stock.

Pharming Group Stock Performance

NASDAQ:PHAR traded down $0.09 during trading hours on Tuesday, hitting $8.80. 2,945 shares of the company traded hands, compared to its average volume of 5,219. Pharming Group has a twelve month low of $6.65 and a twelve month high of $13.20. The stock has a market capitalization of $596.90 million, a price-to-earnings ratio of -33.85 and a beta of 0.05. The firm has a 50-day moving average of $8.28 and a 200 day moving average of $8.13. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41.

Hedge Funds Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 41,110 shares of the company's stock after acquiring an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.